GlassScriptPhysician profile
Tuan Le
NPI 1417210204
$11,749.25
in general payments reported to CMS, 2019-2025
43 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,690 · 2022: $2,529 · 2023: $3,060 · 2024: $2,658 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,527 · Travel and Lodging: $4.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,526.94 |
| Travel and Lodging | $4.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,401.18 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,150.26 | 2021-2025 | Otezla, Evenity, Tepezza |
| Novo Nordisk INC | $1,122.88 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $730.44 | 2021-2025 | Arexvy, Shingrix, Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $680.02 | 2021-2025 | |
| Lilly USA, LLC | $613.32 | 2022-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $599.30 | 2021-2025 | |
| Gilead Sciences, INC. | $371.08 | 2022-2024 | Vemlidy |
| Genzyme Corporation | $365.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.34 | 2021-2024 | Jardiance |
| Nestle Healthcare Nutrition INC. | $311.26 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $298.55 | 2021-2023 | Xarelto |
| Madrigal Pharmaceuticals | $297.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $248.37 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $246.41 | 2022-2023 | Tepezza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $241.28 | 2022-2023 | Dupixent |
| Dexcom, INC. | $233.93 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Redhill Biopharma INC. | $226.99 | 2021-2025 | Talicia |
| Aimmune Therapeutics, INC. | $176.19 | 2024-2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $172.84 | 2023-2024 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $160.73 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Paratek Pharmaceuticals, INC. | $145.35 | 2023-2024 | Nuzyra |
| Agios Pharmaceuticals, INC. | $135.71 | 2024 | Pyrukynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.81 | 2023 | Trulance, Xifaxan |
| Ibsa Pharma INC. | $129.43 | 2023 | Tirosint, Tirosint, Licart |
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
| Ardelyx, INC. | $125.00 | 2024 | Ibsrela |
| Arcutis Biotherapeutics, INC. | $124.58 | 2023 | |
| Neurocrine Biosciences, INC. | $121.09 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $118.02 | 2025 | Symbravo |
| Antares Pharma, INC. | $117.14 | 2023 | Nocdurna, Xyosted, Tlando |
| Sanofi-Aventis U.S. LLC | $105.44 | 2022 | |
| Cequr Corporation | $90.48 | 2023 | Cequr Simplicity |
| Urovant Sciences INC | $80.90 | 2022 | |
| Merck Sharp & Dohme LLC | $38.70 | 2021-2023 | Vaxneuvance |
| Mylan Specialty L.P. | $35.18 | 2021 | |
| Intra-Sana Laboratories | $27.28 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Otsuka America Pharmaceutical, INC. | $26.21 | 2025 | Rexulti |
| Eisai INC. | $22.18 | 2022 | |
| Dynavax Technologies Corporation | $20.56 | 2023 | Heplisav-B |
| Depuy Synthes Sales INC. | $19.16 | 2023 | Orthovisc |
| Idorsia Pharmaceuticals US INC | $14.71 | 2023 | Quviviq |
| Pfizer INC. | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuan Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.